Takeda Sells Canada's Paladin License To Develop Antizol For Japan
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has expanded its license for Antizol (fomepizole) for treating chemical poisoning to Canada's Paladin Labs to develop for the Japanese market